Peptides · Peptide comparison
Capromorelin vs MK-677 (Ibutamoren)
An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.
The oral growth hormone secretagogue that tricks your body into producing more GH — no needles required.
- Growth Hormone
- Growth Hormone
At a glance
Quick comparison
Efficacy
Benefit ratings
GH & IGF-1 Stimulation
Physical Function
Oral Convenience
Muscle and body composition
Recovery and athletic performance
Sleep quality and metabolic health
Technical data
Compound specifications
Capromorelin
- Molecular formula
- C28H35N5O4
- Molecular weight
- 505.6 g/mol
- Half-life
- About 1.2 hours in dogs (ENTYCE label)
- Bioavailability
- 44% oral in dogs and 65% in rats; no human figure published on this page
- CAS number
- 193273-66-4
MK-677 (Ibutamoren)
- Molecular formula
- C27H36N4O5S
- Molecular weight
- 528.7 g/mol
- Half-life
- 4-6 hours (IGF-1 elevation persists ~24 hours)
- Bioavailability
- High oral bioavailability
- CAS number
- 159634-47-6
Protocols
Dosing compared
Capromorelin
Oral
- 3 mgTwice daily · Initial weeksOne of the lower doses tested in the year-long study in older adults; raised growth hormone and IGF-1 [1].
- 10 mgOnce daily at bedtime · OngoingA simple once-daily bedtime dose used in the human trial that improved lean body mass [1].
- 10 mgTwice daily · Up to 12 months in the trialThe highest daily amount studied in older adults (20 mg/day). The trial reported results for the pooled treatment groups, not the largest gains for this dose [1].
MK-677 (Ibutamoren)
Oral
- Weeks 2-410 mgOnce daily · 2-4 weeks initialLower entry dose used in practice to limit water retention and appetite surge before titrating up.
- Studied up to 1-2 years25 mgOnce daily · Studied up to 1-2 years25 mg once-daily oral is the dose used in the randomized trial in healthy older adults; increased GH/IGF-1 and fat-free mass [1]. Most-studied dose [2].
Applications
Best suited for
Capromorelin
- Age-Related Muscle Wasting
- Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.
- Appetite Stimulation
- As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.
- Growth Hormone Research
- One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.
MK-677 (Ibutamoren)
- Older Adults (60+) Seeking Body Composition Improvements
- MK-677 was designed for aging populations. It restores GH and IGF-1 to youthful levels, [7] increases lean mass, and improves physical function in people over 60. A 2-year clinical trial showed a 1.1 kg gain in fat-free mass [1] with only modest fat gain—ideal for maintaining strength in older age.
- Athletes and Fitness Enthusiasts Wanting Recovery Support
- Oral dosing makes MK-677 convenient for athletes. It enhances muscle protein synthesis, speeds recovery after intense training, and supports lean mass building without the hassle of injections.
- People with Chronic Wasting or Protein Deficiency
- Clinical trials show MK-677 helps treat protein-energy wasting in kidney disease and other conditions. [2] It stimulates appetite (a feature in these populations) and preserves muscle tissue—making it useful for those losing mass despite good nutrition.
Safety profile
Side effects
Capromorelin
Common
- Appetite stimulation
- Fluid retention and weight gain
Uncommon
- Joint and muscle aches
- Fatigue or lethargy
- Peripheral edema (swelling)
Serious
- Hyperglycemia
MK-677 (Ibutamoren)
Common
- Increased appetite
- Mild water retention or edema
- Elevated fasting glucose
Uncommon
- Joint or muscle pain
- Carpal tunnel syndrome or nerve compression symptoms
- Mild nausea or digestive upset
Serious
- Glucose dysregulation and diabetes risk
Research status
Safety & evidence
Capromorelin
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Not approved for human use. FDA-approved for veterinary use only: ENTYCE (appetite stimulation in dogs, 2016) and ELURA (weight loss in cats with chronic kidney disease, 2020); both labels state "not for use in humans".
- Safety overview
- Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants. Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.
Contraindications
- Active cancer or history of cancer (GH may stimulate growth)
- Uncontrolled diabetes or severe metabolic disorders
- Severe liver or kidney disease
- Pregnancy and lactation
MK-677 (Ibutamoren)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- MK-677 has been studied in hundreds of humans over 2+ years and is generally well tolerated. [1][3] Most side effects are mild and manageable, especially with lower starting doses. The lack of injection requirement makes it safer than injectable GH in terms of infection risk and sterility concerns. However, it is not FDA approved and should be viewed as a research compound.
Contraindications
- Uncontrolled diabetes or severe glucose dysregulation
- Active cancer or high cancer risk requiring caution with IGF-1 elevation
- Pregnancy or breastfeeding
Decision guide
Which is right for you?
Capromorelin
Choose Capromorelin if…
- Stimulating growth hormone production in elderly adults
- Supporting appetite and weight gain in wasting conditions
- Improving muscle mass and physical performance
- Anti-aging and longevity optimization
MK-677 (Ibutamoren)
Choose MK-677 (Ibutamoren) if…
- Building lean muscle mass and strength
- Improving overall body composition in aging adults
- Enhancing athletic recovery and performance
- Supporting metabolic health and fat loss